Find a Clinical Trial

Filter

Showing 1 - 10 out of 14

Dompe' Reparixin study

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

Moderna mRNA 1273 study

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

COVID-19

All genders

0-12

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

Allogenic Hepatocyte Transplantation into Periduodenal Lymph Nodes

A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease

Liver diseases

All genders

18-70

Recruiting now

Department of Medicine, Division of Gastroenterology + Hepatology

Tufts Medical Center

Learn more

Letermovir for secondary prophylaxis for CMV disease in solid organ transplant recipients

A pilot trial of the tolerability and clinical effectiveness of letermovir when used for secondary prophylaxis to prevent recurrent cytomegalovirus disease in solid organ transplant recipients

Cytomegalovirus infection

All genders

18-75

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

A Long COVID-19 Observational Pilot Study Using Wearable Devices

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

COVID-19 Survivors Registry

National COVID-19 Survivors Registry

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

Armata Bacteriophage Study; disArm Study

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus.

Bacterial infection, Staphylococcus aureus

All genders

18-100

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

VAPOR 2

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

Prostate cancer

All genders

50-89

Recruiting now

Department of Urology

Tufts Medical Center

Learn more

RECOVER VITAL

RECOVER‐VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post‐Acute Sequelae of SARS‐CoV‐2 Infection (PASC)

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Tufts Medical Center

Learn more

Find Care

Services + Treatments

Patients + Visitors

Research + Academics

Clinicians

Find a Clinical Trial

Filter

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

A Phase 2a, Open Label, Dose Escalation Study for Safety, Tolerability, and Efficacy of Hepatocyte Transplantation Into Periduodenal Lymph Nodes Among Subjects With End-Stage Liver Disease

A pilot trial of the tolerability and clinical effectiveness of letermovir when used for secondary prophylaxis to prevent recurrent cytomegalovirus disease in solid organ transplant recipients

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

National COVID-19 Survivors Registry

Prospective, Multicenter, Single-Arm Study of VanquishTM Water Vapor Ablation for PrOstate CanceR

RECOVER‐VITAL: A Platform Protocol for Evaluation of Interventions for Viral Persistence, Viral Reactivation, and Immune Dysregulation in Post‐Acute Sequelae of SARS‐CoV‐2 Infection (PASC)